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Annotation: Chronic hepatitis, cirrhosis of the liver and their consequences remain a global medical and social 
problem in the world. In the clinical practice of previous years, a variety of drugs were used as means of pathogenetic 
therapy, many of which turned out to be ineffective and went out of use. At the same time, widely known data on the 
ability of liver tissue to regenerate allow a rather high assessment of the prospects and potential possibilities of 
pathogenetic therapy of chronic hepatitis and cirrhosis using hepatoprotectors [1.2.5]. 
Drug therapy for patients with liver pathology should always be as economical as possible. In each case, it is 
necessary to compare the degree of necessity of prescribing the drug and the potential danger of its side effects. In the 
treatment of patients with liver diseases, polypharmacy is extremely undesirable, and the prescribed doses, as a rule, 
should not exceed the average therapeutic and course [9.10.12]. 
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1. Relevance of the problem 
Despite the improvement of preventive, therapeutic and diagnostic methods, liver diseases continue to be a 
frequent cause of complications and deaths. In recent years, a number of international and national recommendations 
have been published aimed at optimizing the pharmacotherapy of liver diseases. However, in practice there are 
significant differences between the pharmacotherapy of liver diseases practiced in real clinical conditions and existing 
standards. This dictates the need for pharmacoepidemiological studies aimed at obtaining data on the real practice of 
using drugs for liver diseases, and especially by doctors from rural medical centers, which patients usually turn to. 
Drug therapy for patients with liver pathology should always be as economical as possible. In each case, it  is 
necessary to compare the degree of necessity of prescribing the drug and the potential danger of its side effects. In the 
treatment of patients with liver diseases, polypharmacy is extremely undesirable, and the prescribed doses, as a rule, 
should not exceed the average therapeutic and course 
Management of patients with chronic liver diseases (CHLD) requires significant material costs - this is not only 
payment for treatment, but also indirect costs associated with temporary and permanent disability of the patient. This fact 
necessitates the use by doctors of modern and effective methods for the diagnosis of prevention and СhLD.  
Today, not one new treatment for CHLD can be adopted unless it has been proven to have a positive effect on 
patient survival. This method of evaluating the effectiveness and safety of the drugs used and the method of treatment is 
called "evidence-based medicine. A number of requirements are presented to the pharmacotherapy of ChLD: it must be 
based on the results of evidence-based medicine, be combined, carried out in small doses of drugs and lead to an 
improvement in the quality of life of the patient. 
Based on the foregoing, pharmaco-epidemiological studies play an important role in understanding the problems 
associated with the introduction of patients with CHLD. The lack of independent epidemiological studies of CHLD in 
Uzbekistan does not allow us to fully talk about the detailed characteristics of patients with CHLD, the methods of 
diagnosis used, the nature and results of their treatment. In the analysis of the work carried out in the regions of the 
Republic of Uzbekistan, a number of problems were identified related to the introduction of CHLD: insufficient 
diagnosis of this disease, different approaches to their treatment of the disease, different doses and frequency of use of 
drugs, lack of sufficient control over the dynamics of treatment, polyprogramming, non-identification and lack of 
correction of risk factors and associated pathologies. The above does not allow us to draw final conclusions about the 
situation with the introduction of patients with CHLD in the regions of the republic and especially in the Bukhara and 
Navoi regions. 
The above stated testifies to the relevance of conducting focused research on the use of hepatotropic drugs in 
real medical practice, the results of which allow not only to assess the adequacy of the diagnosis and therapeutic 
measures performed in patients with CHLD, but also to make adjustments to the algorithm for administering patients 
with this pathology and to maintain the gap between everyday clinical practice and achievements of medical science. 
[1,2] 
From the foregoing, it becomes apparent that chronic hepatitis C is a disease requiring a long and expensive treatment 
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and therefore the study of pharmacoeconomics in these patients is very promising [3,4]. 
We previously studied the structure and frequency of drugs used for the treatment of chronic hepatitis C [5,6,7,8,9]. 
The results of these studies required research and the study of pharmacoeconomic aspects of the treatment of this disease. 
The aim of this work was to study and analyze the costs of treatment of chronic hepatitis C in hospital. 
2. Materials and research methods. 
A retrospective study was performed at the Bukhara Regional Multidisciplinary Medical Center, a department 
of gastroenterologists in the period from 2015-2019 with CHLD diseases. Bukhara region analyzed 5000 case histories 
(CHLD) of which 1167 (ChH) were subjected to in-depth study. 
The subject of the study was the drugs used to treat this disease. The cost of acquiring the used medicines was 
calculated taking into account the average market value of the drug corresponding to the hospitalization of the patient period 
and the average length of hospital stay. The obtained results were processed by the method of variation statistics.. 
In connection with the above, we separately studied the structure and costs of individual drugs of first-line drug 
groups for the treatment of chronic hepatitis C. First of all, hepatoprotective drugs were analyzed. The results of this 
analysis are presented in table 1 
 
Table 1: Costs of hepatoprotectors used to treat chronic hepatitis C 












1 Essential 5 ml (№5 in a 
box) 
№5 








2 Carsil tab. (№80 in a box) №8








3 Ursosan cap. (№50 in a 
box) 
№5







4 Hepa-mertz 10мл (№10 in 
a box) 
№1







5 Heptral-400мг (№5 in a 
box) 
№5 






6 Liv-52 (№100 in a box) №1






7 Apcosul (№100 in a box) №1






8 Seripar 5мл (№1 in a box) №1 








As can be seen from the data presented, 8 representatives of hepatoprotectors were mainly used for the treatment 
of chronic hepatitis C. At the same time, the essential drug was Essentiale, Karsil, Ursosan, the “gold standard” in the 
treatment of the pathology under study. Which accounted for 72.0% of the funds for the purchase of hepatoprotectors. 
Apcosul and seripar turned out to be less expensive, which amounted to 1.2% of the spent 
The cost of hepatoprotectors used to treat chronic hepatitis C (in 24186604 thousand soums) funds. At the same 
time, only 28% of the funds for the purchase of hepatoprotectors were spent on the rest of the drugs (hepomerts, heptral, 
liv-52, apcosul.) Therefore, from the group of hepatoprotectors, the most expensive is the essence, for which 4/1 of the 
funds were spent. At the same time, it is required to find out if the costs of this group of drugs are consistent with the 
needs of hospitalized patients. If we take into account that, as a rule, for the treatment of one patient with chronic 
hepatitis C, ursosan capsules are prescribed in doses from 10 mg to 18 mg [14], depending on the severity of the 
pathological process, then in our case 16800 capsules (250 mg each) of ursosan were needed. To purchase this amount of 
the drug was required 22154924sum. However, according to our analysis, over the course of the year, 4400 capsules 
(250 mg each) of ursosan in the amount of 5538731 thousand soums were used, which is only 22.9% of the required cost 
for this drug. Apparently, these results are not due to the low availability of patients with this drug, but rather the 
presence of contraindications for use, the risk of complications, as well as with comorbid conditions. It should be noted 
that the essence was used in injection form, the cost of which amounted to 628852sum. This fact also affects the 
provision of patients with this drug. However, even when summarizing the costs of the injectable and encapsulated form 
of the essence, despite the increase in purchase costs, the minimum proper need of patients for this drug is not covered. 
According to our data, patients with chronic hepatitis C also received hepatamerz, heptral, liv-52, apkasul, the costs of 
which accounted for ¼ of the cost of hepatoprotectors. Given that the vast majority of patients with chronic hepatitis C 
had a severity of the course of the disease, it becomes clear the need for the combined use of two or more 
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In the structure of hepatoprotectors for oral administration, 4 drugs turned out to be costly: karsil, ursosan, 
hepamerts, liv-52 and apkosul (Fig. 6). Karsil and ursosan accounted for 55.9% of the cost of purchasing 
hepatoprotectors for oral administration. Moreover, among these two drugs were the costs of which amounted to almost 
half the costs of these 4 drugs. Therefore, in the structure of treatment of patients with chronic hepatitis C from 
hepatoprotectors for ingestion, more funds were spent on the purchase of drugs with selective action on liver cells and on 
hepatoprotectors with less pronounced side effects. 
 
 
Table 2. Costs of hepatoprotectors, used (per os) for the treatment of chronic hepatitis C (11875620 in thousand 
soums. 




Amount Percentage ratio 
1 Carsil tab. (№80 in a 
box) 
№80 in a box 24590 226 5562918 23% 
2 Ursosan cap. (№50 in 
a box) 
№50 in a box 62500 88 5538731 22.9% 
3 Liv-52 (№100 in a 
box) 
№100 in a box 6200 78 483732 2% 
4 Apcosul (№100 in a 
box) 
№100 in a box 4658 62 290239 1.2% 
 
 
The total number of hepatoprotectors used in patients with chronic hepatitis C during the year, regardless of 
their route of administration, is 1785 injectable form, 454 box of tablet form. Taking into account the probability of a 
combination of enteric and parenteral routes of administration of drugs and an increase in the frequency of their intake 
per day up to 3 times, we separately calculated the coverage of the needs of patients with chronic hepatitis for 
hepatoprotectors. At the same time, it was found that the number of hepatoprotectors we identified provides the need for 
292 patients with chronic hepatitis C. Therefore, the cost of acquiring hepatoprotective, regardless of their dosage forms 
and trade names, theoretically allows you to fully ensure the need for the analyzed patients with chronic hepatitis C for 
drugs from the group of hepatoprotectors. However, it should be borne in mind that not all hepatoprotectors used are 
effective and safe for the body in our case, which requires preliminary differentiation of the hepatoprotectors used, taking 
into account both the peculiarities of the pathology and the organism of patients with chronic hepatitis C. Indeed, the 
importance of hepatoprotector in the treatment of chronic hepatitis C has significantly decreased in recent years due to 
the advent of new effective pathogenetic therapy regimens [15]. Hepatoprotectors in chronic hepatitis C are mainly used 
as pathogenetic therapy and their action is aimed at restoring liver function and reducing the severity of disease 
symptoms..  
3. Conclusions 
          Among the hepatoprotectors prescribed for CHLD in 2015-2019, more than half were drugs containing 
essential phospholipids, which had a better effect on the clinical course of chronic hepatitis of non-viral etiology in the 
form of a decrease in the number of exacerbations and transition to liver cirrhosis. 
         Pharmacoeconomic analysis of drugs used to treat CHLD showed that in 2015-2019, the structure of the 
most expendable drugs (group A) did not show enough for both etiotropic and pathogenetic therapy, minor infusion and 
metabolic drugs prevailed in it. 
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